Rifaximin SSD in Dementia Trial

Description

Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

Conditions

Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia

Rifaximin SSD in Dementia Trial

Condition
Dementia Alzheimer Type
Intervention / Treatment

-

Contacts and Locations

Richmond

Richmond VA Medical Center, Richmond, Virginia, United States, 23249

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate based on Clinical Dementia Rating Scale.
  • * Males and Females Age ≥ 65 years
  • * Community living with availability of caregiver to accompany participant to study visits and to participate in the study.
  • * Able to consent or legal guardian who can consent (with participant assent).
  • * Legally authorized representative (LAR) and caregiver for the study is the same individual.
  • * Fluency (both participant and caregiver) in written and spoken English to participate in study visits.
  • * Dementia not due to AD or VaD
  • * Clinically significant agitation or aggression (requiring treatment with antipsychotic medication)
  • * Delusions and/or hallucinations
  • * Severe psychopathology including major depression
  • * Unstable, severe, or poorly controlled medical conditions evident from physical examination or clinical history
  • * Visual and/or hearing disorder that prevents completion of neuropsychologic evaluations.
  • * Diarrhea
  • * Hypersensitivity to rifaximin, components of rifaximin,
  • * and any rifamycin antimicrobial agent
  • * Antibiotic use in the prior 6 months
  • * Taking medications that interact with Rifaximin. P-glycoprotein (P-gp) inhibitor treatment is permitted as long as the use of P-gp inhibitors is discussed with the investigator.
  • * History of alcohol and/or drug abuse
  • * Participation in another investigational drug trial in the last 30 days

Ages Eligible for Study

65 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jasmohan Bajaj,

Jasmohan Bajaj, PRINCIPAL_INVESTIGATOR, Richmond VA Medical Center

Study Record Dates

2026-05